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rotations positioning during the treatment of MCM using 
VMAT. 
Materials and Methods: Eight treatments of MCM were 
randomly selected from the internal database. These were 
re-planned for single and multiple isocenters (S-iso; M-iso) 
VMAT. The prescription was set to 18Gy at 99% of target 
volume. Paddick conformity index (CI), V100%, V90% for 
target; V4.5Gy, V9Gy, V12Gy for body; beam-on and door-to-
door times were analyzed. For each plan, three shifts (0.5°, 
1°, 2°) were applied for pitch and roll for each isocenter, 
simulating incorrect patient repositioning (1°, 2°) and 
involuntary motion during the delivery (0.5°). The shifted 
plans were recalculated with the same monitor units and 
compared to the reference ones in terms of reduction in 
target volume receiving 90% and 100% of the prescription 
dose. 
Results: A total of 43 metastases were evaluated. No 
significant differences were found in terms of CI between the 
two approaches. M-iso showed significant lower median 
V4.5Gy and V9Gy with respect to S-iso, while S-iso resulted in 
reduced beam on time (7.8±2.8 min vs. 10.4±3.2 min) and 
significant door-to-door time (16.3±2.7 min vs. 27.4±6.2 
min). Concerning the rotated plans, there was a worsening 
with rotation increasing, with median V100% reduction for 2° 
rotations of 22.5% and 2.7% for, respectively, S-iso and M-iso. 
Figure 1 reports the full data analysis on V90% and V100% in 
terms of volume loss. 
 
Figure 1: Delta volume loss for target V90% and V100% in 
function of pitch and roll rotations. 
Conclusions: Adjustments in all six dimensions, including 
unconventional pitch and roll rotations, are fundamental for 
MCM. S-iso reducing delivery time is the treatment of choice 
as the patient comfort is essential for so challenging 
patients. In case of S-iso, on-line patient monitoring during 
the delivery in 6D should be performed to avoid undesirable 
target underdosage. 
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Purpose/Objective: 60-80 patients with an extremity soft 
tissue sarcoma (ESTS) are diagnosed annually in Ireland. At 
least half will require radiotherapy pre or post-operatively. 
Accurate and reproducible patient immobilisation is essential 
for safe delivery of radiotherapy to these patients. However, 
the optimal technique remains to be determined.  
Materials and Methods: Two lower limb immobilisation 
devices are compared in this prospective study. Arm A: is an 
in-house developed device, comprising of customized foot-
orfits and footrests, fixed to the treatment couch. Arm B: is a 
similar device, but has the additional ability to elevate either 
limb independently. 
Results: Preliminary results indicate Arm A is useful for 
proximal thigh/groin sites when limb separation is necessary 
and Arm B is advantageous when treating the distal/anterior 
thigh and calf.  
Arm A: 268 ConeBeamCT (CBCT) scans were analysed on 20 
patients to date. The resultant CTV-PTV margins required for 
setup uncertainty are 0.7, 0.5 and 0.6cm for X, Y, and Z 
directions respectively.  
Arm B: 159 CBCT scans were analysed on 13 patients to date. 
The resultant CTV-PTV margins required for setup uncertainty 
are 0.6, 0.5 and 0.4cm for X, Y, and Z directions 
respectively.  
The standard deviation of the systematic error 
(reproducibility of treatment position) was less for B than for 
A in all directions. Levene’s test for equality/homogeneity of 
variances showed that the variances of the two groups were 
statistically significantly unequal in the z direction (p=.011).  
Conclusions:This research is on-going. Both techniques 
satisfactorily immobilise the lower limb, however the results 
show a smaller CTV-PTV margin could be applied for those 
patients immobilised with the Arm B device. However, at 
present both devices are required. Final results of this 
research study will be available in April 2015; 
recommendations will be made regarding an optimal 
immobilisation device.  
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Purpose/Objective: In 1996 we reported that 63% of 
specimens of mastectomy performed for a unifocal cancer 
harbour other cancer foci; 80% of these foci are in other 
quadrants. In contrast, local recurrence after a lumpectomy 
occurs mainly at the site of the original tumour. Therefore, 
we hypothesized that cancer foci in other quadrants remain 
dormant even in the absence of radiation treatment to the 
whole breast [1]. This academic insight led us to develop the 
targeted intraoperative radiotherapy (TARGIT) technique 
using the Intrabeam device. In the TARGIT A randomized trial 
(n=3451) we compared risk adapted TARGIT vs. whole breast 
radiotherapy [2]. 
Materials and Methods: Randomisation occurred either 
before surgery (Prepathology stratum: TARGIT given during 
lumpectomy) or after surgery (TARGIT given as a delayed 
procedure); the main analysis found that using TARGIT during 
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initial lumpectomy is the preferred option rather than 
delayed administration by reopening the wound. We 
therefore estimated the number of cancer foci in quadrants 
other than the original tumour and compared the incidence 
of recurrence in such quadrants as per treatment received 
(TARGIT vs. EBRT). 
Results: 793 patients in the prepathology stratum 
randomized to TARGIT had only TARGIT as their radiotherapy 
and had. 2098 women years of follow up. The 5 year local 
recurrence rate in those who received TARGIT alone was 2.7% 
(95% CI 1.35.5), which was not different from the whole 
prepathology cohort randomized to TARGIT: 2.1% (1.14.2). In 
these 793 patients, one would expect 63% (i.e., 500) of 
patients to have additional foci of cancer in their breasts and 
80% of these (i.e., 400) should be in quadrants other than the 
index quadrant. In reality, after 2098 women years of follow 
up, 7 patients had recurrence in the scar, 6 had new 
contralateral cancers and 2 had cancers growing in other 
quadrants implying that the remaining 398 foci had remained 
dormant. Amongst 935 patients who received whole breast 
radiotherapy the same number of cancers (n=2) grew in other 
quadrants and there were 5 new contralateral cancers. Of 
note, 94.4% of cases in the TARGIT A trial did not have a 
preoperative MRI, so patients who may have had multicentric 
foci detectable by MRI would have not been excluded from 
the trial. 
Conclusions: Cancer foci in breast that are away from the 
site of the primary tumour remain dormant and behave no 
differently from those in the contralateral breast. They also 
appear to be unaffected by whole breast radiotherapy or are 
treated sufficiently by systemic therapies. This analysis from 
the randomized TARGIT A trial provides further proof 
supporting partial breast irradiation. 
References: 
1. Vaidya JS, Vyas JJ, Chinoy RF, et al. Multicentricity of 
breast cancer: whole organ analysis and clinical implications. 
British Journal of Cancer 1996;74(5):8204.  
2. Vaidya JS, Wenz F, Bulsara M, et al. Risk adapted targeted 
intraoperative radiotherapy versus whole breast radiotherapy 
for breast cancer: 5 year results for local control and overall 
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Purpose/Objective: A joint analysis of clinical and technical 
data from 34 centres within the International Society of 
Intraoperative Radiation Therapy (ISIORT) was undertaken in 
order to identify the range of intraoperative radiotherapy 
(IORT) indications and techniques for various tumour sites. In 
this survey we analysed breast treatments. 
Materials and Methods: Since 2007, we collected 
demographic, clinical and technical data related to IORT 
procedures in a common database. Prospective and 
retrospective data entry was possible. The current study 
analysed 6,816 breast tumours.  
Results: Breast tumours represent 80.3% of all data of the 
ISIORT survey that encompassed 8,493 IORT procedures 
performed from 1992 to 2014. Median age of breast patients 
was 61.1 years (range 16-90). Gender was female in 99.7% 
and male in 0.3% of cases.  
In 6,702 cases (98.3%), IORT was a component of radical 
treatment for primary, newly diagnosed disease and in 114 
cases (1.7%), it was an attempt to rescue localized recurrent 
breast cancer.  
IORT was performed as a boost before or after EBRT in 3,258 
cases (47.8%) with doses of 8–12 Gy. In 3,558 cases (52.6%), 
IORT was used as single radiation treatment modality with 
doses of 18 Gy, 20 Gy or 21 Gy. The patients enrolled in study 
protocols represented 33% of those treated by a single dose 
and 6.3% of those treated by a boost dose.  
IORT was delivered after and before tumour removal in 39% 
and 61% of cases, respectively.  
In 6,406 cases (94%), IORT was performed using electrons of 
4-12 MeV energy. The most used applicators (77% of cases) 
were 5 or 6 cm in diameter and bevel angle was 0° in the 
majority of cases (88%). Four hundred and ten cases (6% of 
patients) were treated with a 50-kV x-ray source in a single 
centre. X-rays treatments were delivered by a spherical 
applicator inserted into the surgical cavity after tumour 
removal.  
Conclusions: At present, the ISIORT database represents the 
largest clinical and technical IORT data collection. 
Breast cancer is the most frequent IORT treatment performed 
in the 34 participating centres. From this analysis, it emerged 
that in most cases IORT was used as single shoot of 18-21 Gy, 
the most employed treatment modality was electron beam 
and the procedure was most frequently performed after 
tumour removal. Only a minority of patients was included in 
clinical trials. 
Further data analyses could enhance multi-institutional 
performance and serve as a basis for designing clinical trials 
in an effort to define the role of IORT in tailored 
multimodality therapeutic approaches. 
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